SLC19A3 (NM_025243) Human Tagged ORF Clone Lentiviral Particle

CAT#: RC206409L4V

  • LentiORF®

Lenti ORF particles, SLC19A3 (mGFP-tagged) - Human solute carrier family 19, member 3 (SLC19A3), 200ul, >10^7 TU/mL

ORF Plasmid: DDK tGFP



Need custom lentivirus service?
Get a free quote

CNY 9,975.00


货期*
详询

规格
    • 200 ul

Product images

经常一起买 (3)
Lenti ORF control particles of pLenti-C-mGFP-P2A-Puro, >1x10^7 TU/ml, 0.5 ml
    • 500 ul

CNY 2,950.00


One-Wash Lentivirus Titer Kit, HIV-1 p24 ELISA
    • 96 reactions

CNY 5,230.00


SLC19A3 Antibody - middle region
    • 100 ul

CNY 5,250.00

Specifications

Product Data
Product Name SLC19A3 (NM_025243) Human Tagged ORF Clone Lentiviral Particle
Synonyms BBGD; THMD2; thTr-2; THTR2
Vector pLenti-C-mGFP-P2A-Puro
ACCN NM_025243
ORF Size 1488 bp
Sequence Data
The ORF insert of this clone is exactly the same as(RC206409).
OTI Disclaimer The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
OTI Annotation This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.
Reference Data
RefSeq NM_025243.3
RefSeq Size 3775 bp
RefSeq ORF 1491 bp
Locus ID 80704
Domains Folate_carrier
Protein Families Transmembrane
MW 55.7 kDa
Gene Summary This gene encodes a ubiquitously expressed transmembrane thiamine transporter that lacks folate transport activity. Mutations in this gene cause biotin-responsive basal ganglia disease (BBGD); a recessive disorder manifested in childhood that progresses to chronic encephalopathy, dystonia, quadriparesis, and death if untreated. Patients with BBGD have bilateral necrosis in the head of the caudate nucleus and in the putamen. Administration of high doses of biotin in the early progression of the disorder eliminates pathological symptoms while delayed treatment results in residual paraparesis, mild cognitive disability, or dystonia. Administration of thiamine is ineffective in the treatment of this disorder. Experiments have failed to show that this protein can transport biotin. Mutations in this gene also cause a Wernicke's-like encephalopathy.[provided by RefSeq, Jan 2010]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.
Customer Reviews 
Loading...